The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Regulatory T-Cell Therapies (Tregs) Market by Target Indications (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), Key Players and Key Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecast, 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2021

  • Pages
    145

  • View Count
    410

Example Insights

Regulatory-T-Cell-Therapies-Market-Context Regulatory-T-Cell-Therapies-Market-List Regulatory-T-Cell-Therapies-Market-Distribution
Regulatory-T-Cell-Therapies-Market-Distribution-by-Company-Size Regulatory-T-Cell-Therapies-Market-Clinical-Research-Landscape Regulatory-T-Cell-Therapies-Market-Partnerships-and-Collaborations
Regulatory-T-Cell-Therapies-Market-Funding-and-Investments Regulatory-T-Cell-Therapies-Market-Porter’s-Five-Forces-Analysis Regulatory-T-Cell-Therapies-Market-Distribution-by-Key-Players

Overview

Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with some form of cancer in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities. The conventional approaches, such as chemotherapy, surgery and radiation therapy, employed for the treatment of oncological indication(s) are considered to be inadequate, specifically for late-stage cancers. Therefore, in recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as Treg cell therapies, that exhibit high efficacy. The Tregs are a mature subpopulation of T-cells that play a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling a balance to homeostasis. In recent years, Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo.      

Over time, more than 90 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective Treg cell therapies against multiple target indications. At present, the pipeline features close to 95 product candidates, and this number is anticipated to grow further in the foreseen future. Of the total candidates, more than 15 Treg therapies, including ALS001 (Coya Therapeutics), CLBS03 (Caladrius Biosciences), ILT-101 (ILTOO Pharma), NKTR-358 (Eli Lilly) and RGI-2001 (REGiMMUNE), are currently being evaluated in advanced stages of development. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials being registered for such candidates. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade. It is also worth highlighting that, in the last five years, capital investments worth around USD 3 billion have been made by strategic investors in this domain. We believe that this niche, but upcoming market, is poised to grow at a healthy pace over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The “Regulatory T-Cell Therapies Market by Target Indications (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), Key Players and Key Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecast, 2021-2035” report features an extensive study of the current market landscape and the associated future potential. The report highlights efforts of both industry players and academic organizations. Amongst other elements, the report features the following:

  • A detailed overview of the current market landscape of Treg cell therapies, along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders,  dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
  • An in-depth analysis of completed, ongoing and planned clinical studies of various Treg cell therapies, based on various relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial recruitment status, study design, average time taken, target patient segment, gender of enrolled patients, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted) and regional distribution of trials. 
  • An analysis of the recent partnerships inked between various players engaged in this domain, during the period 2015-2021 (till August). Additionally, it includes a brief description of various types of partnership models (such as R&D agreements, product development and commercialization agreements, licensing agreements, acquisitions, clinical trial agreements, and manufacturing agreements) that have been adopted by stakeholders, during the given period.
  • A detailed analysis of various investments, such as seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing that were undertaken by companies engaged in this domain, during the period 2014-2021 (till August).
  • Detailed profiles of clinical stage Treg cell therapies (phase I/II or above); each profile features an overview of the therapy, along with information on clinical trials and its endpoints, dosage regimen, key insights and estimated sales revenues (if available).
  • A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
  • Elaborate profiles of prominent players engaged in the development of Treg cell therapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio and recent developments.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall Treg cell therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indication (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), [B] key players and [C] key geographies (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with stakeholders in this domain.

Key Questions Answered

  • What are the prevalent R&D trends related to Treg cell therapies?
  • What are the key therapeutic areas for which Treg cell therapies are being / have been developed?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of Treg cell therapies?
  • What are the key geographies where research focused on Treg cell therapies is being conducted?
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the Treg cell therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of Treg cell therapies. In addition, it includes information on the key characteristics and function of Treg cell therapies, along with information on their mechanism of action and the challenges and future perspectives associated with Treg cell therapies. 

Chapter 4 includes detailed assessment on close to 95 Treg cell therapy candidates that are currently approved or are in different stages of development along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders,  dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).

Chapter 5 provides detailed profiles of clinical stage Treg cell therapies (phase I/II or above); each profile features an overview of the therapy, clinical trial information, clinical trial endpoints, dosage regimen, key insights and estimated sales revenues (if available).

Chapter 6 An in-depth analysis of completed, ongoing and planned clinical studies of various Treg cell therapies, based on various relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial recruitment status, study design, average time taken, target patient segment, gender of enrolled patients, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 7 features an elaborate discussion and analysis of the recent collaborations and partnerships inked between various players engaged in this domain, during the period 2015-2021 (till August). Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product development and commercialization agreements, licensing agreements, acquisitions, clinical trial agreements, manufacturing agreements and others), type of product, target therapeutic area, type of partner, key players and regional distribution of the collaborations.

Chapter 8 provides details on the various investments and grants that have been awarded to players focused on the development of Treg cell therapies. It includes a detailed analysis of the funding instances that have taken place during the period 2014 to 2021 (till August), highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain. 

Chapter 9 provides insights on a qualitative analysis highlighting five competitive forces in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.

Chapter 10 includes brief profiles of prominent players engaged in the development of Treg cell therapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio and recent developments.

Chapter 11 features an elaborate discussion on the future commercial opportunity offered by Treg cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indication (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), [B] key players and [C] key geographies (North America, Europe and Asia Pacific)

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Pascal Merchiers (Chief Scientific Officer, Oncurious).

Chapter 14 is an appendix, which provides miscellaneous charts and figures, list of figures, list of tables and list of companies and organizations.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Regulatory T-Cell Therapies
3.2. Characteristics of Treg Cell Therapies
3.3. Function of Treg Cell Therapies 
3.4 Mechanism of Action of Treg Cell Therapies 
3.5 Advantages of Treg Cell Therapies
3.6 Challenges and Future Perspectives Associated with Treg Cell Therapies

4. MARKET LANDSCAPE
4.1. Treg Cell Therapies: Overall Market Landscape
4.1.1. Analysis by Type of Product
4.1.2. Analysis by Phase of Development
4.1.3. Analysis by Therapeutic Area
4.1.4. Analysis by Phase of Development and Therapeutic Area
4.1.5. Analysis by Target Indication
4.1.6. Analysis by Source of T-Cells 
4.1.7. Analysis by Route of Administration
4.1.8. Analysis by Dose Frequency
4.1.9. Analysis by Target Patient Segment
4.1.10. Analysis by Type of Therapy
4.1.11. Analysis by Type of Developer
4.1.12. Leading Industry Players: Analysis by Number of Treg Cell Therapies
4.1.13. Leading Non-Industry Players: Analysis by Number of Treg Cell Therapies
4.2. Treg Cell Therapies: List of Developers
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Regional Landscape of Developers

5. THERAPY PROFILES
5.1. arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network)
5.1.1. Company Overview
5.1.2. Therapy Overview
5.1.3. Clinical Trial Information 
5.1.4. Clinical Trial Endpoints
5.1.5. Dosage Regimen

5.2. CLBS03 (Caladrius Biosciences)
5.2.1. Company Overview
5.2.2. Therapy Overview
5.2.3. Clinical Trial Information
5.2.4. Clinical Trial Endpoints
5.2.5. Dosage Regimen
5.2.6. Key Insights
5.2.7. Estimated Sales Revenue

5.3. ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.3.1. Company Overview
5.3.2. Therapy Overview
5.3.3. Clinical Trial Information
5.3.4. Clinical Trial Endpoints
5.3.5. Dosage Regimen
5.3.6. Estimated Sales Revenue

5.4. Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.4.1. Company Overview
5.4.2. Therapy Overview
5.4.3. Clinical Trial Information
5.4.4. Clinical Trial Endpoints
5.4.5. Dosage Regimen
5.4.6. Key Insights

5.5. NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly)
5.5.1. Company Overview
5.5.2. Therapy Overview
5.5.3. Clinical Trial Information
5.5.4. Clinical Trial Endpoints
5.5.5. Dosage Regimen
5.5.6 Key Insights
5.5.7. Estimated Sales Revenue

5.6. RGI-2001 (REGiMMUNE)
5.6.1. Company Overview
5.6.2. Therapy Overview
5.6.3. Clinical Trial Information
5.6.4. Clinical Trial Endpoints
5.6.5. Dosage Regimen
5.6.6. Key Insights
5.6.7. Estimated Sales Revenue

5.7. rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.7.1. Company Overview
5.7.2. Therapy Overview
5.7.3. Clinical Trial Information
5.7.4. Clinical Trial Endpoints
5.7.5. Dosage Regimen
5.7.6. Estimated Sales Revenue

5.8. TR004 (Miltenyi Biotec)
5.8.1. Company Overview
5.8.2. Therapy Overview
5.8.3. Clinical Trial Information 
5.8.4. Clinical Trial Endpoints
5.8.5. Dosage Regimen
5.8.6. Estimated Sales Revenue

5.9. TX200 (Sangamo Therapeutics)
5.9.1 Company Overview
5.9.2. Therapy Overview
5.9.3. Clinical Trial Information
5.9.4. Clinical Trial Endpoints
5.9.5. Dosage Regimen
5.9.6. Key Insights

5.10. VT301 / GB301 (VT Bio / BHT Lifescience Austrailia)
5.10.1. Company Overview
5.10.2. Therapy Overview
5.10.3. Clinical Trial Information 
5.10.4. Clinical Trial Endpoints
5.10.5. Dosage Regimen

6. CLINICAL TRIAL ANALYSIS
6.1. Methodology and Parameters 
6.2. Treg Cell Therapies: Snapshot of Clinical Trials (till July 2021)
6.2.1. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Phase and Enrolled Patient Population
6.2.4. Analysis by Trial Recruitment Status
6.2.5. Analysis by Year and Trial Recruitment Status

6.2.6. Analysis by Type of Allocation
6.2.7. Analysis by Purpose of Study 
6.2.8. Analysis by Type of Masking
6.2.9 Analysis by Intervention Model
6.2.10. Analysis by Year and Trial Phase
6.2.11. Analysis by Year, Average Time Taken and Trial Phase 
6.2.12. Analysis by Target Patient Segment
6.2.13. Analysis by Gender of Enrolled Patients 
6.2.14. Analysis by Type of Sponsor(s)
6.2.15. Leading Non-Industry Players: Analysis by Number of Trials Registered
6.2.16. Leading Industry Players: Analysis by Number of Trials Registered
6.2.17. Analysis by Location of Trial
6.2.18. Analysis by Trial Status and Geography

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Treg Cell Therapies: Partnerships and Collaborations
7.2.1 Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Year and Type of Partnership 
7.2.4. Analysis by Type of Product
7.2.5. Analysis by Year and Type of Product
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Type of Partner 
7.2.8. Analysis by Type of Partner and Type of Partnership
7.2.9. Leading Industry Players: Analysis by Number of Partnerships
7.2.10. Region-wise Distribution
7.2.11. Country-wise Distribution

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Treg Cell Therapies: Funding and Investment
8.2.1. Analysis by Year of Investment and Amount Invested
8.2.2. Analysis by Type of Funding
8.2.3. Analysis by Year of Investment and Type of Funding
8.2.4. Analysis by Type of Product
8.2.5. Analysis by Year of Investment and Type of Product 
8.2.6. Analysis by Type of Investor
8.2.7. Leading Investors: Analysis by Number of Funding Instances
8.2.8. Leading Players: Analysis by Number of Funding Instances
8.2.9. Analysis by Geography

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3 Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of Developers
9.3.3. Bargaining Power of Customers
9.3.4. Threat of Available Substitute Therapies 
9.3.5. Rivalry Among Existing Competitors 

10. COMPANY PROFILES
10.1. Abata Therapeutics
10.1.1. Company Overview
10.1.2. Key Insights
10.1.3. Product Portfolio
10.1.4 Recent Developments and Future Outlook

10.2. Cellenkos
10.2.1. Company Overview
10.2.2. Key Insights
10.2.3. Product Portfolio
10.2.4 Recent Developments and Future Outlook

10.3. Coya Therapeutics
10.3.1. Company Overview
10.3.2. Key Insights
10.3.3. Product Portfolio
10.3.4 Recent Developments and Future Outlook

10.4. ILTOO Pharma
10.4.1. Company Overview
10.4.2. Key Insights
10.4.3. Product Portfolio
10.4.4 Recent Developments and Future Outlook

10.5. NEKTAR
10.5.1. Company Overview
10.5.2. Key Insights
10.5.3. Product Portfolio
10.5.4 Recent Developments and Future Outlook

10.6. Roche
10.6.1. Company Overview
10.6.2. Key Insights
10.6.3. Financial Information
10.6.4 Product Portfolio
10.6.5 Recent Developments and Future Outlook

10.7. Sonoma Biotherapeutics
10.7.1. Company Overview
10.7.2. Key Insights
10.7.3. Product Portfolio
10.7.4 Recent Developments and Future Outlook

10.8. TeraImmune
10.8.1. Company Overview
10.8.2. Key Insights
10.8.3. Product Portfolio
10.8.4 Recent Developments and Future Outlook

10.9. TRACT Therapeutics
10.9.1. Company Overview
10.9.2. Key Insights
10.9.3. Product Portfolio
10.9.4 Recent Developments and Future Outlook

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Treg Cell Therapies Market, 2021-2030
11.2.1. Treg Cell Therapies Market: Analysis by Type of Product
11.2.2. Treg Cell Therapies Market: Analysis by Target Indication
11.2.3. Treg Cell Therapies Market: Analysis by Key Players
11.2.4. Treg Cell Therapies Market: Analysis by Geography
11.2.5. Treg Cell Therapies: Forecast of Individual Product Sales
11.2.5.1. CLBS03 (Caladrius Biosciences): Estimated Sales Revenues
11.2.5.2. ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Estimated Sales Revenues
11.2.5.3. NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Estimated Sales Revenues
11.2.5.4. RGI-2001 (REGiMMUNE): Estimated Sales Revenues
11.2.5.5. rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Estimated Sales Revenues
11.2.5.6. TR004 (Miltenyi Biotec): Estimated Sales Revenues
11.2.5.7. VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Estimated Sales Revenues

12. CONCLUSION

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Oncurious
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Pascal Merchiers, Chief Scientific Officer

14. APPENDICES
14.1 Miscellaneous Charts and Figures
14.2 List of Figures
14.3 List of Tables
14.4 List of Companies and Organizations

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investments
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Classification of Treg Cells
Figure 3.2 Function of Treg Cell Therapies
Figure 3.3 Mechanism of Action of Treg Cell Therapies
Figure 3.4 Advantages of Treg Cell Therapies
Figure 4.1 Treg Cell Therapies: Distribution by Type of Product
Figure 4.2 Treg Cell Therapies: Distribution by Phase of Development
Figure 4.3 Treg Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 Treg Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 Treg Cell Therapies: Distribution by Target Indication
Figure 4.6 Treg Cell Therapies: Distribution by Source of T-Cell
Figure 4.7 Treg Cell Therapies: Distribution by Route of Administration
Figure 4.8 Treg Cell Therapies: Distribution by Dose Frequency
Figure 4.9 Treg Cell Therapies: Distribution by Target Patient Segment
Figure 4.10 Treg Cell Therapies: Distribution by Type of Therapy
Figure 4.11 Treg Cell Therapies Distribution by Type of Developer
Figure 4.12 Leading Industry Players: Distribution by Number of Treg Cell Therapies
Figure 4.13 Leading Non-Industry Players: Distribution by Number of Treg Cell Therapies
Figure 4.14 Treg Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.15 Treg Cell Therapy Developers: Distribution by Company Size
Figure 4.16 Treg Cell Therapy Developers: Distribution by Location of Headquarters
Figure 4.17 Treg Cell Therapy Developers: Regional Landscape of Developers
Figure 5.1 CLBS03: Estimated Sales Revenue
Figure 5.2 ILT-101: Estimated Sales Revenue
Figure 5.3 NKTR-358 / LY3471851: Estimated Sales Revenue
Figure 5.4 RGI-2001: Estimated Sales Revenue
Figure 5.5 rhIL-2: Estimated Sales Revenue
Figure 5.6 TR004: Estimated Sales Revenue
Figure 5.7 VT301 / GB301: Estimated Sales Revenue
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.5 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 6.7 Clinical Trial Analysis: Distribution by Purpose of Study
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Masking
Figure 6.9 Clinical Trial Analysis: Distribution by Intervention Model
Figure 6.10 Clinical Trial Analysis: Distribution by Year and Trial Phase
Figure 6.11 Clinical Trial Analysis: Distribution by Year, Average Time Taken and Trial Phase
Figure 6.12 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 6.13 Clinical Trial Analysis: Distribution of Enrolled Patients by Gender
Figure 6.14 Clinical Trial Analysis: Distribution by Type of Sponsor(s)
Figure 6.15 Leading Non-Industry Players: Distribution by Number of Trials Registered
Figure 6.16 Leading Industry Players: Distribution by Number of Trials Registered
Figure 6.17 Clinical Trial Analysis: Distribution by Location of Trial
Figure 6.18 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 7.5 Partnerships and Collaborations: Distribution by Year and Type of Product
Figure 7.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.8 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.9 Leading Industry Players: Distribution by Number of Partnerships
Figure 7.10 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 7.11 Partnerships and Collaborations: Distribution by Geography (Country-wise)
Figure 8.1 Funding and Investment: Distribution by Year of Investment and Amount Invested
Figure 8.2 Funding and Investment: Distribution of Instances by Type of Funding
Figure 8.3 Funding and Investment: Distribution of Amount Invested by Type of Funding
Figure 8.4 Funding and Investment: Distribution by Year of Investment and Type of Funding
Figure 8.5 Funding and Investment: Distribution by Type of Product
Figure 8.6 Funding and Investment: Distribution by Year of Investment and Type of Product
Figure 8.7 Funding and Investment: Distribution by Type of Investor
Figure 8.8 Leading Investors: Distribution by Number of Funding Instances
Figure 8.9 Leading Players: Distribution by Number of Funding Instances
Figure 8.10 Funding and Investment: Distribution of Amount Invested by Region
Figure 8.11 Funding and Investment: Distribution by Geography (Country-wise)
Figure 9.1 Porter’s Five Forces Analysis
Figure 10.1 Roche: Annual Revenues, 2017-2020 (USD Billion)
Figure 11.1 Overall Treg Cell Therapies Market, 2021-2035 (USD Million)
Figure 11.2 Treg Cell Therapies Market, 2021-2035: Distribution by Type of Product (USD Million)
Figure 11.3 Treg Cell Therapies Market, 2021-2035: Distribution by Target Indication (USD Million)
Figure 11.4 Treg Cell Therapies Market, 2021-2035: Distribution by Key Players (USD Million)
Figure 11.5 Treg Cell Therapies Market, 2021-2035: Distribution by Geography (USD Million)
Figure 11.6 CLBS03 (Caladrius Biosciences): Sales Forecast, 2021-2035 (USD Million)
Figure 11.7 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Sales Forecast, 2021-2035 (USD Million)
Figure 11.8 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Sales Forecast, 2021-2035 (USD Million)
Figure 11.9 RGI-2001 (REGiMMUNE): Sales Forecast, 2021-2035 (USD Million)
Figure 11.10 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Sales Forecast, 2021-2035 (USD Million)
Figure 11.11 TR004 (Miltenyi Biotec): Sales Forecast, 2021-2035 (USD Million)
Figure 11.12 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Sales Forecast, 2021-2035 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Funding and Investments
Figure 12.4 Concluding Remarks: Clinical Trial Analysis
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Characteristics of Treg Cell Therapies
Table 4.1 List of Treg Cell Therapies
Table 4.2 List of Treg Cell Therapy Developers
Table 5.1 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Clinical Trial Information
Table 5.2 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Clinical Trial Endpoints
Table 5.3 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Dosage Regimen
Table 5.4 CLBS03 (Caladrius Biosciences): Clinical Trial Information
Table 5.5 CLBS03 (Caladrius Biosciences): Clinical Trial Endpoints
Table 5.6 CLBS03 (Caladrius Biosciences): Dosage Regimen
Table 5.7 CLBS03 (Caladrius Biosciences): Key Insights
Table 5.8 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.9 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.10 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.11 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.12 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.13 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.14 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Key Insights
Table 5.15 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Clinical Trial Information
Table 5.16 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Clinical Trial Endpoints
Table 5.17 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Dosage Regimen
Table 5.18 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Key Insights
Table 5.19 RGI-2001 (REGiMMUNE): Clinical Trial Information
Table 5.20 RGI-2001 (REGiMMUNE): Clinical Trial Endpoints
Table 5.21 RGI-2001 (REGiMMUNE): Dosage Regimen
Table 5.22 RGI-2001 (REGiMMUNE): Key Insights
Table 5.23 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.24 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.25 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.26 TR004 (Miltenyi Biotec): Clinical Trial Information
Table 5.27 TR004 (Miltenyi Biotec): Clinical Trial Endpoints
Table 5.28 TR004 (Miltenyi Biotec): Dosage Regimen
Table 5.29 TX200 (Sangamo Therapeutics): Clinical Trial Information
Table 5.30 TX200 (Sangamo Therapeutics): Clinical Trial Endpoints
Table 5.31 TX200 (Sangamo Therapeutics): Dosage Regimen
Table 5.32 TX200 (Sangamo Therapeutics): Key Insights
Table 5.33 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Clinical Trial Information
Table 5.34 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Clinical Trial Endpoints
Table 5.35 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Dosage Regimen
Table 5.36 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Key Insights
Table 6.1 Treg Cell Therapies: Snapshot of Clinical Trials
Table 7.1 Treg Cell Therapies: Partnerships and Collaborations
Table 8.1 Treg Cell Therapies: Funding and Investment
Table 10.1 Abata Therapeutics: Product Portfolio
Table 10.2 Abata Therapeutics: Recent Developments and Future Outlook
Table 10.3 Cellenkos: Product Portfolio
Table 10.4 Cellenkos: Recent Developments and Future Outlook
Table 10.5 Coya Therapeutics: Product Portfolio
Table 10.6 Coya Therapeutics: Recent Developments and Future Outlook
Table 10.7 ILTOO Pharma: Product Portfolio
Table 10.8 ILTOO Pharma: Recent Developments and Future Outlook
Table 10.9 NEKTAR: Product Portfolio
Table 10.10 NEKTAR: Recent Developments and Future Outlook
Table 10.11 Roche: Product Portfolio
Table 10.12 Roche: Recent Developments and Future Outlook
Table 10.13 Sonoma Biotherapeutics: Product Portfolio
Table 10.14 Sonoma Biotherapeutics: Recent Developments and Future Outlook
Table 10.15 TeraImmune: Product Portfolio
Table 10.16 TeraImmune: Recent Developments and Future Outlook
Table 10.17 TRACT Therapeutics: Product Portfolio
Table 10.18 TRACT Therapeutics: Recent Developments and Future Outlook
Table 14.1 Appendices

List Of Companies

  1. 8VC
  2. Abata Therapeutics
  3. Abingworth
  4. Accelerate NY Seed Fund
  5. Access Biotechnology
  6. ADC Therapeutics
  7. Advantech Capital
  8. Advent France Biotechnology
  9. Agenus
  10. Ain Shams University
  11. Alderaan Biotechnology
  12. Alexandria Venture Investments
  13. Allele Capital Partners
  14. Alliancells-PuRui Biocience 
  15. Ankara University
  16. ARCH Venture Partners
  17. Assistance Publique - Hôpitaux de Paris
  18. Assiut University
  19. Autoimmunity Centers of Excellence (ACE)
  20. Avidity Partners
  21. Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
  22. Baylor College of Medicine
  23. Bayside Health & Rehabilitation Center
  24. BeiGene
  25. Beijing Ditan Hospital
  26. Beijing Tongren Hospital
  27. Belgian Hematology Society
  28. Benaroya Research Institute at Virginia Mason (BRI)
  29. Beth Israel Deaconess Medical Center
  30. BHT LIFESCIENCE AUSTRALIA
  31. Bioinova
  32. Boston Children's Hospital
  33. Boston Immune Technologies and Therapeutics (BITT)
  34. Boxer Capital
  35. Bpifrance
  36. Brigham and Women's Hospital
  37. Bristol-Myers Squibb
  38. Brugmann University Hospital
  39. Cairo University
  40. Caladrius Biosciences
  41. California Institute for Regenerative Medicine
  42. Cambridge University Hospitals NHS Foundation Trust
  43. Cancer Prevention Research Institute of Texas
  44. CDH Investments
  45. Celgene
  46. Celldex Therapeutics
  47. Cellenkos
  48. Center Eugene Marquis
  49. Center for Cell and Gene Therapy
  50. Central South University
  51. Centre Hospitalier du Valais Romand
  52. Centre Hospitalier Universitaire de NÄ«mes
  53. Centre Hospitalier Universitaire de Nice
  54. Centre Hospitalier Universitaire de Saint-Etienne
  55. Centre Hospitalier Universitaire Dijon
  56. Charité – Universitätsmedizin Berlin
  57. Chia Tai Tianqing Pharmaceutical
  58. China Life Private Equity Investment Company 
  59. Chinese PLA General Hospital
  60. Chulalongkorn University
  61. Country Garden Venture Capital
  62. Coya Therapeutics
  63. CRISPR Therapeutics
  64. Dana-Farber Cancer Institute
  65. DCVC Bio
  66. Diabetes Research Institute Foundation Canada (DRIFCan)
  67. Duke University
  68. Dutch Cancer Society
  69. EcoR1 Capital
  70. EDBI
  71. Efung Capital
  72. Egle Therapeutics 
  73. EGP 
  74. ElevateBio
  75. Eli Lilly
  76. Emerson Collective
  77. Emory University School of Medicine
  78. Entos Pharmaceuticals
  79. EpiVax
  80. European Commission
  81. F2 Ventures
  82. FairJourney Biologics
  83. Fakultas Kedokteran Universitas Indonesia (FKUI)
  84. Fidelity Research & Management Company
  85. Flanders Innovation and Entrepreneurship
  86. Fondation ARSEP
  87. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  88. Fondazione Italiana Sclerosi Multipla
  89. Forge Biologics
  90. Franklin Templeton Investments
  91. Friedreich’s Ataxia Research Alliance (FARA)
  92. FUNDACION FAMILIA ALONSO
  93. Fundación Pública Andaluza para la Gestión de la (FISEVI)
  94. GEMABIOTECH
  95. GentiBio
  96. GIC
  97. Gilead Sciences
  98. Greater Bay Area Investments Groups
  99. Greater Paris University Hospitals
  100. GTJA Investment Group
  101. Guy's and St Thomas' NHS Foundation Trust
  102. H. Lee Moffitt Cancer Center and Research Institute
  103. Hackensack Meridian Health
  104. Hanmi Pharmaceuticals
  105. Hannover Medical School
  106. Harbour BioMed
  107. Hatteras Venture Partners
  108. Hoffmann-La Roche
  109. Horatio Ventures NYC.
  110. Hospital de Santa Maria
  111. Hospital General Universitario Gregorio Marañón
  112. Hualan Genetic
  113. Hudson Bay Capital
  114. Hunan Xeno Life Science
  115. Icahn School of Medicine at Mount Sinai
  116. ILTOO Pharma
  117. Immune Tolerance Network
  118. Imperial College London
  119. Indoor Biotechnologies
  120. Incyte
  121. Inria
  122. Inserm
  123. Institut Polyclinique de Cannes (IPOCA)
  124. Institute of Hematology and Blood Diseases Hospital
  125. Instituto de Medicina Molecular JoÃo Lobo Antunes
  126. Instituto de Salud Carlos III
  127. IONTAS 
  128. Instituto Português de Oncologia de Lisboa (IPO Lisboa)
  129. Instituto Portugues De Oncologia Do Porto Francisco Gentil
  130. IQVIA
  131. IRCCS Azienda Ospedaliero Universitaria di Bologna
  132. IRCCS Ospedale San Raffaele
  133. IRCCS Policlinico San Matteo
  134. ITOCHU
  135. Japan Asia Investment 
  136. JDRF T1D Fund
  137. Tianhe Stem Cell Biotechnologies
  138. Jonsson Comprehensive Cancer Center
  139. Jounce Therapeutics
  140. JT New Century
  141. Jules Bordet Institute
  142. Junten Bio
  143. Juntendo University
  144. Juvenile Diabetes Research Foundation
  145. Kaiser Foundation Hospital 
  146. Kaiser Permanente 
  147. King's College London
  148. Kurume University
  149. Kyverna Therapeutics
  150. Lausanne University Hospital
  151. Legend Capital
  152. Liana's Dream Foundation
  153. LifeForce Capital
  154. Lightspeed Venture Partners
  155. Lilly Asia Ventures
  156. Loyola University
  157. Lyell Immunopharma
  158. MD Anderson Cancer Center
  159. Maastricht University Medical Center
  160. Mahidol University
  161. Maisonneuve-Rosemont Hospital
  162. MANRESANA de MICOBACTERIOLOGIA
  163. Mashhad University of Medical Sciences
  164. Massachusetts General Hospital Cancer Center
  165. Matrix Capital Management
  166. MD Anderson Cancer Center
  167. Medical Research Council
  168. Medical University of Graz
  169. Medical University of Lodz
  170. Medical University of Vienna
  171. Medicxi
  172. Mesoblast
  173. Methodist Health System
  174. MIGAL Galilee Research Institute 
  175. Milky Way Ventures
  176. Miltenyi Biomedicine
  177. Miltenyi Biotech
  178. Mission BioCapital (formerly known as BioInnovation Capital)
  179. Mogrify
  180. Moleculin Biotech
  181. Morningside Venture Investments
  182. Mount Sinai Hospital
  183. MPM Capital
  184. Mubadala Investment Company
  185. Nanjing Medical University
  186. National Cancer Institute
  187. National Health Security Office (NHSO)
  188. National Heart, Lung, and Blood Institute (NHLBI)
  189. National Institute for Health Research
  190. National Institute of Allergy and Infectious Diseases (NIAID)
  191. National Institutes of Health (NIH)
  192. NIH Clinical Center (CC)
  193. National Multiple Sclerosis Society
  194. National Natural Science Foundation of China
  195. National Taiwan University Hospital
  196. ND Capital
  197. Nektar Therapeutics
  198. New Enterprise Associates
  199. New Leaf Venture Partners
  200. NextWavebio
  201. Nicoya Lifesciences
  202. Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS)
  203. Northwestern University
  204. Nova Immunotherapeutics
  205. Novartis Pharmaceuticals
  206. Novartis Venture Fund
  207. Numeric Biotech
  208. NYU Langone’s Perlmutter Cancer Center
  209. Octagon Capital
  210. Oncurious
  211. OrbiMed
  212. Orbis Medical Centre
  213. Orca Bio
  214. Pandion Therapeutics (acquired by Merck)
  215. Pierre and Marie Curie University
  216. Pirogov Russian National Research Medical University
  217. PLA Navy General Hospital
  218. Polaris Partners
  219. Prometheus Laboratories
  220. Quell Therapeutics
  221. RA Capital Management
  222. Radboud University
  223. Rapa Therapeutics
  224. RAPT Therapeutics
  225. Redmile Group
  226. REGiMMUNE
  227. Rho Federal Systems Division
  228. Roche
  229. Royan Institute
  230. Russian Academy of Medical Sciences
  231. Sage Partners
  232. Samsara BioCapital
  233. Sanford Burnham Prebys Medical Discovery Institute
  234. Sanford health
  235. Sangamo Therapeutics
  236. Scale AI
  237. Seattle Children’s Research Institute
  238. Second Xiangya Hospital of Central South University
  239. Selexis 
  240. Servier
  241. Seventh Framework Programme
  242. Shandong University
  243. Shanghai Institute of Acupuncture, Moxibustion and Meridian
  244. Sheffield Institute for Translational Neuroscience
  245. Sir Jules Thorn Charitable Trust
  246. SK Holdings
  247. Small Business Administration
  248. Small Business Innovation Research (SBIR)
  249. SMBC Venture Capital
  250. Sonoma Biotherapeutics
  251. SR One
  252. St George Street Capital
  253. St. George's Hospital
  254. St. Jude Children's Research Hospital
  255. Stanford University
  256. State-Financed Health Facility “Samara Regional Medical Center Dinasty”
  257. Sumitomo Mitsui Banking Corporation (SMBC)
  258. Surveyor Capital
  259. Syncona
  260. Tabriz University of Medical Sciences
  261. Takeda
  262. Tanta University
  263. Targazyme
  264. TeraImmune
  265. The Egyptian IVF-ET Center
  266. The Faculty of Medicine Siriraj Hospital
  267. The First Affiliated Hospital of Soochow University
  268. The Invus Group
  269. The Leona M. and Harry B. Helmsley Charitable Trust
  270. The Methodist Hospital Research Institute
  271. TRACT Therapeutics
  272. TregTherapeutics
  273. Tusk Therapeutics (acquired by Roche)
  274. TxCell
  275. University Hospital Regensburg
  276. University Hospital of Bordeaux
  277. University Hospital of Montpellier
  278. University of Alberta
  279. University of Bergen
  280. University of Bologona
  281. University of California, San Francisco
  282. University of Cambridge
  283. University of Chicago
  284. University of Colorado
  285. University of Erlangen-Nuremberg
  286. University of Illinois Chicago
  287. University of Kentucky
  288. University of Liege
  289. University of London
  290. University of lowa College of Pharmacy
  291. University of Minnesota
  292. University Of Minnesota Medical School
  293. University of Nottingham
  294. University of Naples Federico II
  295. University of Perugia
  296. University of Regensburg
  297. University of Texas
  298. University of Texas
  299. University of Washington
  300. University of Zurich
  301. Université Paris-Est Créteil
  302. VA Office of Research and Development
  303. Versant Ventures
  304. Vertex Ventures
  305. Vida Ventures
  306. Vir Biotechnology
  307. VT BIO
  308. Washington University School of Medicine
  309. Wellcome Trust
  310. Westlake Village BioPartners
  311. Xian Janssen Pharmaceutical
  312. Yale University
  313. Zhejiang University
  314. Zheshang Venture Capital
  315. Zhongyuan Union Stem Cell Bioengineering

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com